Lundbeck

pivot change turnaround direction walk away
Biotech

Lundbeck ends subcutaneous migraine cohort after futility review

The Danish drugmaker switched its focus to IV delivery after seeing phase 2b data, delaying the completion of the trial in the process.
Nick Paul Taylor Apr 1, 2025 5:00am
stop shut down close end button

Lundbeck slashes value of $250M Abide buyout after pain setback

Oct 24, 2024 7:20am
graphic of the brain and the electrical signals that make it up

Lundbeck signs $2.5B check for Longboard and its epilepsy med

Oct 14, 2024 8:30am
AI artificial intelligence drug development computational biology machine learning

Lundbeck taps Charles River for AI-enabled neuro drug discovery

Oct 2, 2024 9:21am
art psychedelic hallucinogen

Otsuka takes on new Mindset for $59M, delving into psychedelics

Sep 1, 2023 10:55am
parasail Blue Lagoon parachute

Abbvie's president adds COO title—Chutes & Ladders

Jun 30, 2023 9:30am